The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]
The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]
Cassandra Gorsuch, PhD, chief scientific officer at Precision Biosciences, discussed the company’s ARCUS gene editing platform, its innovative approach to treating Duchenne muscular dystrophy, and promising preclinical data presented at MDA 2025.
The professor of neurology at the University of Texas Health Science Center San Antonio discussed some of the challenges with therapeutic development for OPMD, as well as advances and barriers to gene therapy approaches. [WATCH TIME: 4 minutes]
The clinical associate professor of neurology and neurosurgery at NYU Langone Health emphasized the importance of rapid, targeted blood pressure reduction and bundled care to improve outcomes in patients with intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.
The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]
Harmony Biosciences’ phase 3 study will assess EPX-100, a repurposed antihistamine, as a potential treatment for Lennox-Gastaut syndrome, targeting seizure reduction and improved outcomes.
The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.
Murali Doraiswamy, MD, MBBS, a professor of psychiatry and geriatrics at Duke University School of Medicine, gave clinical follow-up on a pivotal analysis of the phase 3 APOLLOE4 study testing a novel therapeutic for Alzheimer disease.
Newly presented open-label extension results at AAN 2025 suggest that investigational ZYN002, a cannabidiol gel, may help improve irritability in children and adolescents living with Fragile X syndrome.
The staff scientist at Gladstone Institutes talked about leveraging AI-driven behavioral analysis to better model and assess Alzheimer disease progression in preclinical studies. [WATCH TIME: 2 minutes]
Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.
The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]
The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]
The clinical professor of stroke neurology and neurocritical care at Stanford University advocated for early and intensive blood pressure reduction in patients with intracerebral hemorrhage to limit hematoma expansion and improve outcomes. [WATCH TIME: 5 minutes]
The ENABLE phase 4 study will evaluate the real-world safety, efficacy, and patient experience of ublituximab in relapsing multiple sclerosis over a 96-week period.
Presented at the 2025 AAN Annual Meeting, findings from a phase 3 study showed that a single 30 mg/kg dose of ANX005 significantly improved health outcomes in Guillain-Barré syndrome, with benefits seen as early as week 1 and sustained over 6 months.
Findings showed that atogepant 60 mg once daily demonstrated significant improvements in functional outcomes for patients with episodic migraine, compared with placebo, over 12 weeks.
Long-term data from a phase 2 study extension suggest that frexalimab, a CD40L inhibitor, maintains disease control and is well-tolerated in relapsing multiple sclerosis, reinforcing its potential as a next-generation treatment.
Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.
A recent large-scale analysis presented at the 2025 AD/PD Conference highlighted the role of coping strategies in mitigating negative outcomes.
Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.
A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.
An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.
A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.
The Spectris device demonstrated preserved corpus callosum structure and correlated sensory-evoked gamma oscillations in patients with Alzheimer disease, highlighting its potential neuroprotective effects.
Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.
The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.
